Novartis Q3 Performance
Novartis' Q3 performance was fueled by fast growth of recently label-expanded drugs, despite generic competition affecting established blockbusters.
Net sales for the Swiss big pharma company rose 7% in constant currencies to $13.9bn in Q3, approximately in line with Wall Street forecasts. Core operating income reached $5.46bn in the quarter, just slightly above consensus analyst predictions of $5.4bn.
Oncology Segment Growth
Drugs from Novartis' oncology segment spurred much of the growth, with breast cancer treatment Kisqali (ribociclib) growing by 68% in Q3 2025 compared to Q3 2024.
The gold standard of business intelligence.
Author's summary: Novartis' Q3 performance driven by new drugs growth.
More News
- Charlie Kirk’s accused killer allowed to wear street clothes in court
- Al Nassr Al-Ittihad Jeddah 28 10 2025 Live Score and Match Summary
- Trump administration quietly purges ICE leaders in five cities, including Denver: Sources
- Tomago Aluminium is more than just a smelter, it's a strategic asset
- The Most Dazzling Looks From The Angel Ball's 2025 Red Carpet
- The Angel Ball Honors Tina Knowles
- Sudan: North Darfur capital falls to RSF as UN warns of 'atrocities and mass displacement'
- Eintracht Frankfurt Borussia Dortmund 28 10 2025 Live Score and Match Summary
- Al-Nassr 1-2 Al-Ittihad: Report, result and goals as Karim Benzema scores to knock Cristiano Ronaldo's side out of Kings Cup
- Looking back: Local ghost legends